Elekta and IBA collaborate to optimize quality assurance in radiation therapy
STOCKHOLM – Elekta (EKTA-B.ST) announced today it has entered into a collaborative agreement with IBA to optimize quality assurance (QA) solutions. Radiation therapy departments and clinics using Elekta’s treatment delivery systems will benefit from QA solutions that are designed for these devices by streamlining workflows and improving access to measurement data.
Maurits Wolleswinkel, Chief Product Officer at Elekta, said: “With this agreement, IBA will provide dosimetric QA solutions, fully interoperable with Elekta treatment delivery systems, so our customers can be sure that the devices supplied work with our systems to yield enhanced data analytics. Elekta customers will benefit from this agreement by receiving a streamlined QA solution in a one-stop shop.”
IBA is already a provider of dosimetry QA equipment to radiation therapy clinics using Elekta linear accelerators worldwide. Interoperability of the systems is well-established, and the collaboration will make it possible to further develop integrated solutions to the benefit of Elekta patients.
Jean-Marc Bothy, President of IBA Dosimetry, said: “This is a great chance to simultaneously provide independent and integrated quality assurance. We are dedicated to delivering customer-first service, meaningful innovation and flexible solutions that are easy to use for our global customer base. Together with Elekta, we will work on future solutions to continuously improve the combination of treatment and independent quality assurance.”
# # #
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: Central European Time (CET)
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: Eastern Time (ET)
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 120 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on Twitter.